Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model

Drug Development and Industrial Pharmacy

Volumn 36, Issue 3, 2010, Pages 315-322

  Tamhane, Mitalee ^a   Chakilam, Ananthsrinivas R ^b   Jayaraj, Andrew ^b   Thakkar, Vineet ^b   Taft, David R ^a  

^a LONG ISLAND UNIVERSITY   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

Cimetidine; Drug drug interaction; Probenecid; Renal excretion; Transport

Indexed keywords

CIMETIDINE; METHOTREXATE; PROBENECID; VX 702; ANTIRHEUMATIC AGENT; CARBANILAMIDE DERIVATIVE; ENZYME INHIBITOR; IMMUNOLOGIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG INHIBITION; DRUG TISSUE LEVEL; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY PERFUSION; KIDNEY TUBULE ABSORPTION; MALE; NONHUMAN; RAT; URINARY EXCRETION; ALGORITHM; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; GLOMERULUS FILTRATION RATE; KIDNEY; KINETICS; METABOLISM; OSMOLARITY; PERFUSION; PHYSIOLOGY; SPRAGUE DAWLEY RAT; ULTRAFILTRATION;

ALGORITHMS; ANIMALS; ANTIRHEUMATIC AGENTS; CIMETIDINE; DRUG INTERACTIONS; ENZYME INHIBITORS; GLOMERULAR FILTRATION RATE; IMMUNOLOGIC FACTORS; KIDNEY; KINETICS; MALE; METHOTREXATE; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; OSMOLAR CONCENTRATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERFUSION; PHENYLUREA COMPOUNDS; PROBENECID; RATS; RATS, SPRAGUE-DAWLEY; ULTRAFILTRATION;

EID: 77249170824     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903154200     Document Type: Article

References (19)

1. Vakily M, Amer F, Kukulka MJ, Andhivarothai N. (2005). Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J Clin Pharmacol, 45:1179-1186
2. Statkevich P, Fournier DJ, Sweeney KR. (1993). Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. J Phamacol Exp Ther, 265:1118-1124
3. Uwai Y, Saito H, Inui K. (2000). Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol, 409:31-36 (Pubitemid 30950633)
4. Thyss A, Kubar J, Milano G, Namer M, Schneider M. (1986). Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet, 327:256-258
5. Mandel MA. (1976). The synergistic effect of salicylates on methotrexate toxicity. Plast Reconstr Surg, 57:733-737
6. Fang P-T, Leong K-H. (2007). The use of biological agents in the treatment of rheumatoid arthritis. Ann Acad Med Singapore, 36:128-134
7. Kaminska B. (2005). MAPK signaling pathways as molecular targets for anti-inflammatory therapy: From molecular mechanisms to therapeutic benefits. Biochim Biophys Acta, 1754:253-262
8. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner C-W, Bitzan P, et al. (2000). Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum, 43:2501-2512
9. Morel J, Berenbaum F. (2004). Signal transduction pathways: New targets for treating rheumatoid arthritis. Joint Bone Spine, 71:503-510 (Pubitemid 39626717)
10. Damjanov N, Kauffman RS, Spencer-Green GT. (2009). Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum, 60:1232-1241
11. Bekersky I. (1983). Use of the isolated perfused kidney as a tool in drug disposition studies. Drug Metab Rev, 145:931-960
12. Taft DR. (2004). The isolated perfused rat kidney model: A useful tool for drug discovery and development. Curr Drug Discov Technol, 1:97-111.
13. Bowman RH. (1975). The perfused rat kidney. Methods Enzymol, 39:3-11.
14. Nishiitsutsuji-Uwo JM, Ross BD, Krebs HA. (1967). Metabolic activities of the isolated perfused rat kidney. Biochem J, 103:852-862
15. Poola NR, Bhuyian D, Ortiz S, Savant IA, Sidhom M, Taft DR, et al. (2002). A novel HPLC assay for pentamidine: Comparative effects of creatinine and inulin on GFR estimation and pentamidine renal excretion in the isolated perfused rat kidney. J Pharm Pharm Sci, 5:135-145
16. Tucker GT. (1981). Measurement of the renal clearance of drugs. Br J Pharmacol, 12:761-770
17. Lee W, Kim RB. (2004). Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol, 44:137-166
18. Shitara Y, Horie T, Sugiyama Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci, 27:425-446
19. Karpf DM, Kirkegaard AL, Evans AM, Nation RL, Hayball PJ, Milne RW. (2003). Effect of ketoprofen and its enantiomers on the renal disposition of methotrexate in the isolated perfused rat kidney. J Pharm Pharmacol, 55:1641-1646